title: Androgens regulate TRAIL-induced cell death in prostate cancer cells via multiple mechanisms.
abstract: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising therapeutic agent for prostate cancer because it selectively induces apoptosis in cancer cells but not in normal cells. Previous reports have suggested that androgens regulate TRAIL-induced apoptosis in prostate cancer cells. However, there are discrepancies between these reports of how androgens affect TRAIL-induced cell death. To clarify the role of androgens on TRAIL-induced apoptosis in prostate cancer cells, we investigated the effects of androgen on TRAIL-induced cell death in a dose-response manner. Our results showed that although androgens sensitize LNCaP cells to TRAIL-induced apoptosis, this effect is dose-dependent and biphasic. We found that low levels of androgen are superior to high levels of androgen in term of sensitizing LNCaP cells to TRAIL. We also found that upregulation of DR5 (TRAIL-R2) expression by androgens is critical for sensitizing LNCaP cells to TRAIL. However, low levels of androgen are sufficient to induce DR5 expression and sensitize LNCaP cells to TRAIL-induced cell death. High levels of androgen alter the TRADD/RIP1 ratio, which may contribute to NF-κB activation and sequentially inhibit TRAIL-induced apoptosis.
authors: Department of Urology Research/Biochemistry, Mayo Clinic, Rochester, MN 55905, USA.
authors: Diping
authors: D
authors: Wang
authors: Ji
authors: J
authors: Lu
authors: Donald J
authors: DJ
authors: Tindall
mesh_terms: D000730:Androstadienes / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D008297:Male; D015741:Metribolone / Q000494:pharmacology*; D016328:NF-kappa B / Q000378:metabolism; D028861:Nuclear Pore Complex Proteins / Q000378:metabolism; D011471:Prostatic Neoplasms; D016601:RNA-Binding Proteins / Q000378:metabolism; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D053199:TNF Receptor-Associated Death Domain Protein / Q000378:metabolism; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000494:pharmacology*; D045165:Testosterone Congeners / Q000494:pharmacology* / Q000502:physiology; D000077191:Wortmannin
chemical_list: C119724:AGFG1 protein, human; D000730:Androstadienes; D000970:Antineoplastic Agents; D016328:NF-kappa B; D028861:Nuclear Pore Complex Proteins; D016601:RNA-Binding Proteins; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D053199:TNF Receptor-Associated Death Domain Protein; D053221:TNF-Related Apoptosis-Inducing Ligand; C105190:TNFRSF10A protein, human; D045165:Testosterone Congeners; D015741:Metribolone; D000077191:Wortmannin
references: Cancer Cell Int. 2011 Dec 02;11:42
references: 22136382
references: Cancer Res. 2009 Dec 15;69(24):9448-56
references: 19934328
references: Cell Death Differ. 2011 Mar;18(3):538-48
references: 21072056
references: Oncogene. 2001 Jun 28;20(29):3757-65
references: 11439339
references: Exp Oncol. 2005 Jun;27(2):120-4
references: 15995629
references: Clin Cancer Res. 2007 Dec 1;13(23):7181-90
references: 18056199
references: Prostate. 1997 Sep 1;32(4):284-93
references: 9288188
references: FASEB J. 2011 Apr;25(4):1353-8
references: 21187341
references: Prostate. 1996 Nov;29(5):296-302
references: 8899002
references: Cell. 1995 May 19;81(4):495-504
references: 7758105
references: Mol Cell Biol. 2006 May;26(9):3505-13
references: 16611992
references: Cancer Res. 2001 Jul 15;61(14):5611-8
references: 11454715
references: Cancer Treat Rev. 2009 May;35(3):280-8
references: 19117685
references: Oncogene. 2001 May 17;20(22):2826-35
references: 11420694
references: Prostate. 2006 Jun 15;66(9):987-95
references: 16541419
references: Apoptosis. 2005 Dec;10(6):1411-8
references: 16215673
references: J Biol Chem. 2005 Jan 21;280(3):2205-12
references: 15520016
references: J Mol Med (Berl). 2007 Sep;85(9):923-35
references: 17437073
references: Front Biosci. 2006 May 01;11:1549-68
references: 16368536
references: Oncogene. 2004 Sep 30;23(45):7494-506
references: 15326475
references: Science. 1997 Apr 4;276(5309):111-3
references: 9082980
references: Int J Cancer. 2009 Aug 15;125(4):932-41
references: 19422047
references: Oncogene. 2008 Jul 24;27(32):4422-33
references: 18391984
references: Mol Cancer Ther. 2004 Jul;3(7):803-12
references: 15252141
references: Int J Oncol. 2002 Jul;21(1):111-7
references: 12063557
references: Drug Resist Updat. 2008 Feb-Apr;11(1-2):17-24
references: 18374623
references: J Interferon Cytokine Res. 2001 May;21(5):313-22
references: 11429162
references: Cancer Biol Ther. 2002 Nov-Dec;1(6):631-7
references: 12642685
references: Oncogene. 2005 Oct 13;24(45):6773-84
references: 16007156
references: Nat Rev Cancer. 2008 Jan;8(1):61-70
references: 18075512
references: Mol Endocrinol. 2005 Jul;19(7):1792-802
references: 15731171
references: Prostate. 2008 Nov 1;68(15):1696-706
references: 18726983
references: J Biol Chem. 2001 Apr 6;276(14):10767-74
references: 11278284
references: FEBS Lett. 2011 Jul 21;585(14):2144-50
references: 21627969
references: Prostate. 2007 Aug 1;67(11):1194-201
references: 17520660
references: J Biol Chem. 2006 Sep 22;281(38):27882-93
references: 16870607
references: Cancer Res. 2008 Jul 1;68(13):5469-77
references: 18593950
references: J Biol Chem. 2001 Oct 19;276(42):38361-9
references: 11461904
references: Oncogene. 2001 Sep 20;20(42):6073-83
references: 11593415